Prøve GULL - Gratis

Bio Spectrum - February 2022

Gå ubegrenset med Magzter GOLD

Lese Bio Spectrum sammen med 9000+ andre magasiner og aviser med bare ett abonnement

Se katalog

1 måned

$14.99

1 år $149.99

$149.99

$12/month

(OR)

Abonner kun på Bio Spectrum

Gave Bio Spectrum

Avbryt når som helst.

(Ingen forpliktelser) ⓘ

Hvis du ikke er fornøyd med abonnementet, kan du sende oss en e-post på help@magzter.com innen 7 dager etter abonnementets startdato for full refusjon. Ingen spørsmål - lover! (Merk: Gjelder ikke for enkeltutgavekjøp)

Digitalt abonnement

Øyeblikkelig tilgang ⓘ

Abonner nå for å begynne å lese umiddelbart på Magzter-nettstedet, iOS, Android og Amazon-appene.

Verifisert sikker

betaling ⓘ

Magzter er en verifisert Authorize.Net-forhandler. Les mer

I dette nummeret

DRUG WAR INTENSIFIES
The pandemic has entered yet another phase, with the Omicron variant wreaking havoc across the globe. The high infection rate of this new cause for concern, in India, has also triggered a ‘war of medical opinions’ between the Indian Council of Medical Research (ICMR) and the Drugs Controller General of India (DCGI). Pharma majors are churning out viable treatment options at a feverish pace, in a bid to become the most widely accepted drug listed in COVID-19 treatment protocols. Merck’s Molnupiravir is one such drug that is embroiled in a ‘safety vs efficacy’ contest. Let’s investigate further

Bio Spectrum Description:

Forlegger: MM-Activ-Sci-Tech-Communication

Kategori: Business

Språk: English

Hyppighet: Monthly

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.